Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial
Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...
Збережено в:
| Автори: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2018-10-01
|
| Серія: | Frontiers in Neurology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/article/10.3389/fneur.2018.00842/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|